PTC Therapeutics, Inc.

NASDAQ (USD): PTC Therapeutics, Inc. (PTCT)

Last Price

48.40

Today's Change

-1.46 (2.92%)

Day's Change

47.76 - 49.50

Trading Volume

575,770

Overview

Market Cap

3 Billion

Shares Outstanding

77 Million

Avg Volume

816,709

Avg Price (50 Days)

40.89

Avg Price (200 Days)

34.37

PE Ratio

-8.15

EPS

-5.94

Earnings Announcement

26-Feb-2025

Previous Close

49.86

Open

48.53

Day's Range

47.76 - 49.5

Year Range

23.58 - 54.16

Trading Volume

575,770

Price Change Highlight

1 Day Change

-2.93%

5 Day Change

8.11%

1 Month Change

18.42%

3 Month Change

53.16%

6 Month Change

27.37%

Ytd Change

72.61%

1 Year Change

94.07%

3 Year Change

30.88%

5 Year Change

-2.08%

10 Year Change

-2.22%

Max Change

193.51%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment